See ACURATE neo2 in action
“From a surgical point of view we use supra-annular [valves] due to greater orifice area, minimizing the risk of PPM (Prosthesis-Patient Mismatch) – it’s better for the patient.”
- Prof. Michael Zembala
The self-expanding, supra-annular valve structure reduces the risk of structural valve deterioration. ACURATE neo2™ has demonstrated large EOAs and low mean gradients up to 5 years.1 Large EOAs provide improved flow, less resistance, and better long-term durability.2
ACURATE neo2 vs. SAPIEN 3 Ultra
First real-world analysis of device success and clinical safety in next-gen TAVI devices: the comparison of supra-annular ACURATE neo2 and intra-annular SAPIEN 3 Ultra valves.1
Elevated gradients*¹
Severe prosthesis-patient mismatch¹
1. Kim WK., et al. Multicenter comparison of latest generation of self-expanding versus balloon-expandable transcatheter aortic valves. Euro PCR 2022.
2. Flameng W, et al. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. 2010 May 3;121:2123-2129.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service